Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
Clinical trial NCT07397819 · RECRUITING
Trial details
- NCT number
- NCT07397819
- Sponsor
- Dong sheng Zhang
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-28
- Primary completion
- 2028-06-30
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.